Articles By Cathy Yarbrough`

  1. From Windowless Data Room To The CEO's Office 1/1/2016

    Kurt Graves, the 47-year-old chairman, president, and CEO of Boston-based Intarcia Therapeutics, got his first major break in the life sciences industry 25 years ago as a sales representative for Merck in his home state of Michigan.

  2. A Life Sciences Start-Up Learns To Pivot And Overcome Adversity 7/1/2015

    Jonathan Lim, M.D., was only 31 years old when he was appointed Halozyme Therapeutics’ first president and CEO in 2003. During the previous two years, he was a management consultant at McKinsey & Company, advising C-suite executives of both start-ups and Fortune 500 companies in the healthcare industry. But, prior to Halozyme, which is headquartered in San Diego, Lim had not worked at a biotech or pharmaceutical company.

  3. Search For New Therapeutic Targets Turns To “Loss-Of- Function” DNA Variants 5/4/2015

    Fifteen years ago at a White House ceremony announcing the completion of the Human Genome Project’s draft of the human DNA sequence, President Bill Clinton told the audience of industry and academic leaders, government officials, and journalists that “today’s historic achievement is only a starting point. There is much hard work yet to be done.”

  4. How BARDA Is Helping Speed Up Drug Development/Manufacture 3/30/2015

    An unusual federal government agency, the Biomedical Advanced Research and Development Authority (BARDA), is providing funding and technical expertise to more than 85 pharmaceutical and biotech companies and 25 academic organizations.

  5. Patient-Focused Drug Development: To Understand Patients, You Must Engage Them 1/31/2015

    When National Health Council (NHC) official Marc Boutin, J.D., speaks to an audience of pharmaceutical company executives about patient-focused drug development, he underscores the topic’s importance to the life sciences industry by stating, “Look at the person sitting on your right. Now, look at the person sitting on your left. One of them likely will be unemployed in five years.”

  6. Novel Financing For Gene Therapy Company 4/30/2014

    Gene therapy pioneer Katherine High, M.D., was looking forward to her first meeting in 2011 with Jeffrey Marrazzo, then a consultant to the CEO of Children’s Hospital of Philadelphia (CHOP). A veteran of three life sciences companies, Marrazzo was meeting with Dr. High and other CHOP leaders to identify potential new revenue streams for the hospital.

  7. Competitors Collaborate To Train Asian Workers In Clinical Trials 1/6/2014

    Competing pharmaceutical companies typically don’t share with each other. An exception is the Asia Training Consortium (ATC), whose members share their best practices in employee training to address a common challenge: preparing their Asian workers to manage the clinical trials that the companies plan to sponsor in the part of the world that is widely regarded as having the greatest potential for economic growth for the pharmaceutical industry.

  8. Adaptive Clinical Design Addresses The Uncertainties 10/3/2013

    When a traditional, randomized, controlled clinical trial fails, it’s not unusual for the study manager to commend, “if I knew before the trial what I know now, the tiral would have been planned differently.” To avoid this post-trial scenario biopharma companies are adopting adaptive clinical-trials designs which allow managers to predict what they likely will regret at the end of the study

  9. Sanofi Pharma R&D, The Case For Change Was Not Hard To Make 7/31/2013

    Sanofi will be the most productive and profitable R&D operation in the biopharmaceutical industry in 2015. That’s the vision of Elias Zerhouni, M.D., the company’s president of global R&D, and Sanofi CEO Chris Viehbacher, who persuaded Zerhouni, the former NIH director, to leave the world of academia where he had built a reputation as an innovative, successful, and charismatic leader.

  10. Why Regulatory Intelligence Is More Important Than Ever 4/1/2013

    Global regulatory drug development is more complex than ever before. Regulatory professionals must understand the hot button issues that affect the review of new drug applications in global regions.